kabutan

Nxera Pharma Co., Ltd.(4565) Summary

4565
TSE Prime
Nxera Pharma Co., Ltd.
849
JPY
+30
(+3.66%)
Dec 5, 12:45 pm JST
5.47
USD
Dec 4, 10:45 pm EST
Result
PTS
outside of trading hours
849
Dec 5, 12:45 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.17
Yield
ー%
Margin Trading Ratio
456.65
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
822 JPY 5.29 USD
Previous Close Dec 4
819 JPY 5.27 USD
High Dec 5, 9:31 am
864 JPY 5.56 USD
Low Dec 5, 9:00 am
822 JPY 5.29 USD
Volume
560,300
Trading Value
0.47B JPY 3.06M USD
VWAP
846.07 JPY 5.45 USD
Minimum Trading Value
84,900 JPY 547 USD
Market Cap
0.08T JPY 0.50B USD
Number of Trades
796
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
High
1-Year Average
1,285
1-Year High Jun 2, 2025
4,353
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 185,300 5,274,200 28.46
Nov 21, 2025 174,200 4,942,800 28.37
Nov 14, 2025 154,700 4,895,200 31.64
Nov 7, 2025 155,400 5,010,600 32.24
Oct 31, 2025 155,300 4,656,400 29.98
Company Profile
Nxera Pharma Co., Ltd. is a drug discovery venture specializing in the development of drugs targeting membrane protein GPCRs in areas such as neurology, immunology, and gastroenterology.
Sector
Pharmaceuticals
Nxera Pharma Co., Ltd. is a biopharmaceutical company with a core focus on a drug discovery platform targeting GPCRs (G protein-coupled receptors), handling everything from research and development to sales of pharmaceuticals. The company is actively pursuing a growth strategy through acquisitions. Its UK subsidiary is responsible for drug discovery, translational medicine, preclinical and early clinical development. Clinical development and sales in Japan and Korea are managed by a wholly-owned subsidiary based in Japan and a subsidiary based in Korea, respectively. The company also envisions future business expansion into the APAC (Asia-Pacific) region. Nxera Pharma's strengths lie in GPCR structural analysis using StaR technology, early-stage lead compound generation, and candidate exploration. The company has established a global drug discovery network.